SCHEMBL30219064

CSCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 10)

	gene	UniProt	supporting neighbours	confidence
▸	CALCR	P30988	4/20	0.71

▸	GLP1R	P43220	9/20	0.68

▸	GCGR	P47871	6/20	0.68

▸	APLNR	P35414	2/20	0.62

▸	CRHR1	P34998	1/20	0.61

▸	CRHR2	Q13324	1/20	0.61

▸	HCRTR1	O43613	1/20	0.60

▸	HCRTR2	O43614	1/20	0.60

▸	CXCR4	P61073	1/20	0.60

▸	GIPR	P48546	3/20	0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30231506	1.00	CALCR (0.71)	CALCRGLP1RGCGRAPLNRCRHR1
Acetic Acid SCHEMBL30219057	0.99	CALCR (0.70)	CALCRGLP1RGCGRAPLNRCRHR1
Acetic Acid SCHEMBL30219038	0.99	CALCR (0.70)	CALCRGLP1RGCGRAPLNRCRHR1
SCHEMBL30219087	0.99	CALCR (0.71)	CALCRGLP1RGCGRAPLNRCRHR1
SCHEMBL30231481	0.99	CALCR (0.71)	CALCRGLP1RGCGRAPLNRCRHR1
Acetic Acid SCHEMBL30219088	0.99	CALCR (0.70)	CALCRGLP1RGCGRAPLNRCRHR1
Acetic Acid SCHEMBL30219069	0.99	CALCR (0.70)	CALCRGLP1RGCGRAPLNRCRHR1
SCHEMBL38659902	0.95	CALCR (0.67)	CALCRGLP1RGCGRAPLNRCRHR1
SCHEMBL30862308	0.93	CALCR (0.68)	CALCRGLP1RGCGRAPLNRCXCR4
SCHEMBL30432942	0.92	CALCR (0.68)	CALCRGLP1RGCGRCRHR1CRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2026102332-A1	NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF	Blaze Bioscience, Inc. (US)	2026-05-15	—	—	WO	disclosed
EP-3046572-B1	CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF	BLAZE BIOSCIENCE INC (US)	2025-07-30	—	—	EP	disclosed
US-20250115648-A1	CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF	BLAZE BIOSCIENCE INC (US)	2025-04-10	—	—	US	disclosed
US-12048732-B2	Methods of treating breast cancer	Blaze Bioscience, Inc. (US)	2024-07-30	—	—	US	disclosed
US-12048750-B2	Tissue-homing peptide conjugates and methods of use thereof	Blaze Bioscience, Inc. (US)	2024-07-30	—	—	US	disclosed
US-20230257428-A1	METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES	Blaze Bioscience, Inc.	2023-08-17	—	—	US	disclosed
US-20230211000-A1	TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF	Blaze Bioscience, Inc.	2023-07-06	—	—	US	disclosed
US-20230037660-A1	METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS	Blaze Bioscience, Inc.	2023-02-09	—	—	US	disclosed
US-11559580-B1	Tissue-homing peptide conjugates and methods of use thereof	Blaze Bioscience, Inc. (US)	2023-01-24	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12048750-B2	Tissue-homing peptide conjugates and methods of use thereof	CXCL12, CCL2, CD44	CALCR 701/4885GLP1R 1298/4885GCGR 1801/4885
US-20230211000-A1	TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF	CXCL12, CCL2, CD44	CALCR 701/4885GLP1R 1298/4885GCGR 1801/4885
US-11559580-B1	Tissue-homing peptide conjugates and methods of use thereof	CXCL12, CCL2, CD44	CALCR 701/4885GLP1R 1298/4885GCGR 1801/4885
US-20230257428-A1	METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES	CHLSN, SLC47A1, CLSPN	CALCR 1387/4885GLP1R 1922/4885GCGR 2218/4885
US-20230037660-A1	METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS	FLT4, FLT1, KDR	CALCR 452/4885GLP1R 831/4885GCGR 2154/4885
US-12048732-B2	Methods of treating breast cancer	BRCA1, HUNK, MLEC	CALCR 1367/4885GLP1R 954/4885GCGR 1274/4885
US-20250115648-A1	CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF	CHLSN, QPCT, CBX6	CALCR 1052/4885GLP1R 1489/4885GCGR 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.